Hekun decoction versus Femoston for women with amnestic mild cognitive impairment in early menopause: a randomized, three-arm, double-blind clinical trial.

ABSTRACT:

Background

Amnestic mild cognitive impairment (aMCI), a prodromal stage of Alzheimer's disease (AD), carries a high risk of progression to dementia. However, few clinical trials have focused on interventions to delay this progression. Hekun Decoction, an herbal-based oral medicine, has shown potential in improving memory loss during early menopause. Here we performed a randomized controlled trial to evaluate the efficacy and safety of Hekun Decoction in women with aMCI.

Methods

This prospective, randomized, three-arm, double-blind clinical trial enrolled women aged 40-60 years with aMCI during early menopause. Participants were randomized to Hekun Decoction, Femoston, or placebo for 24 weeks. The primary outcome was the change in the Montreal Cognitive Assessment (MoCA) scor

SUBMITTER: Zhai Z 

PROVIDER: S-EPMC12463637 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature